Telix Receives European Approval for Prostate Cancer Imaging Agent
Illuccix secures European marketing approval, advancing prostate cancer imaging standards.
Telix has achieved a pivotal milestone with the European approval of Illuccix® (gallium-68 gozetotide injection), a cutting-edge imaging agent for prostate cancer. This decision follows the successful completion of a decentralized procedure (DCP) led by Germany’s BfArM and agreed upon by 18 other European Economic Area (EEA) member states. Illuccix is now set to enter the administrative phase for national implementation, paving the way for its commercial launch across Europe.
Kevin Richardson, CEO of Telix Precision Medicine, expressed optimism about the approval, stating, "Illuccix brings a transformative prostate cancer imaging solution to patients and clinicians, aligning with European guidelines for superior diagnostic accuracy." PSMA-PET imaging has redefined prostate cancer management, offering unparalleled precision in staging and detecting disease recurrence. This breakthrough enhances clinical decision-making, replacing older methods like bone and CT scans, and sets a new benchmark for prostate cancer care.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Mehr aus Pharma News
Alle Beiträge →
Medicus Pharma reicht Phase‑2b/3‑Protokoll für Teverelix bei der FDA ein
Fresenius Kabi erhält FDA-Warnschreiben nach Fehlern bei der Untersuchung aseptischer Verarbeitung in der Anlage Melrose Park
Discussion